Standout Papers

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC 2021 2026 2022 2024168
  1. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC (2021)
    Tianqing Chu, Runbo Zhong et al. Journal of Thoracic Oncology

Immediate Impact

1 by Nobel laureates 57 standout
Sub-graph 1 of 24

Citing Papers

The hallmarks of cancer immune evasion
2024 Standout
The B7:CD28 family and friends: Unraveling coinhibitory interactions
2024 Standout
2 intermediate papers

Works of Wei Nie being referenced

A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab
2020
B and T Lymphocyte Attenuator is a Target of miR-155 during Naïve CD4+ T Cell Activation.
2016

Author Peers

Author Last Decade Papers Cites
Wei Nie 420 351 254 61 787
Pietro De Placido 461 376 229 49 764
Yongfeng Yu 400 388 353 63 822
Shun Lu 380 336 292 49 844
Elvire Pons‐Tostivint 448 337 233 46 735
Chih‐Liang Wang 337 327 336 58 816
Ruochuan Zang 397 318 391 38 832
Wen Liu 501 203 398 58 849
Yaokai Wen 270 279 233 44 723
Rosario García Campelo 286 256 260 64 652
Jianguo Sun 410 320 278 57 878

All Works

Loading papers...

Rankless by CCL
2026